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ABSTRACT 
 
In the emerging era of genomics-driven medicine, tumor genomic profiling in 
particular has begun to revolutionize the field of oncology.  As the integration of such 
technologies evolves and affects the management and treatment of cancer, questions arise 
with regards to the changing roles of healthcare professionals involved in cancer care.  
One hundred and twenty-eight members of the National Society of Genetic Counselors 
(NSGC) responded to a survey to assess the current roles of genetic counselors in 
oncology and the perceived roles that genetic counselors will have in the clinical use of 
tumor genomic profiling.  With regards to current roles in cancer care, the majority 
reported that they provide genetics cancer-related expertise to other medical professionals 
(85.0%, n=85).  With respect to perceived roles in the clinical use of tumor genomic 
sequencing, most responders (80.0%, n=80) indicated that they feel there is a role for 
genetic counselors.  The majority of responders identified 5 roles that genetic counselors 
would be equipped to play in regard to tumor genomic analysis.  The largest number, 91 
(97.9%) report identifying and discussing incidental germline findings uncovered by 
testing, followed by serving as a resources for physicians who may not be comfortable 
with genomic testing 76.3% (n=71), educating medical students, residents and fellows 
about tumor genomic sequencing 69.9% (n=65), educating medical professionals on 
issues around informed consent 67.7% (n=63), and post-test counseling of patients to 
help interpret tumor sequencing results 65.6% (n=61).  The duty of pre-test counseling 
for patients to help explain tumor sequence testing and informed consent is reported as a 
significant role by smaller numbers of responders 44.1% (n=41).  When prompted to 
choose the most significant, the majority (56.7%, n=51) report identifying and discussing 
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incidental germline findings as the primary role.  Responses show that participants 
foresee multiple duties that genetic counselors are adept to handle in the context of tumor 
genomic analysis, with information involving germline findings specified as the most 
important and relevant to the training of genetic counselors. 
 
KEY WORDS: 
Next-generation sequencing, Tumor genomic profiling, Genetic counselors, Germline 
findings 
 
INTRODUCTION 
Considerable attention has been given to the field of oncology in the emerging era 
of genomics-driven medicine.  Since cancer is a disease of the genome, oncology is at the 
frontline of the personalized healthcare movement (Garraway, Verweij, & Ballman, 
2013).  President Obama has made it a priority to fund scientific research during his 
administration, and his Precision Medicine Initiative (PMI) promotes the shift in medical 
practice from a “one-size-fits-all” strategy to a more tailored approach, taking into 
account each individual’s genetic makeup (or the genetic profile of an individual’s tumor) 
(White House, Office of the Press Secretary, January 30, 2015).  
Although cancer largely arises as a result of the accumulation of genomic damage 
that one acquires throughout life, each cancer has its own genetic makeup.  Accordingly, 
genome-profiling technologies play an integral role in the emerging field of “precision 
oncology” as described by editors Garraway, Verweijj and Ballman (2013), in the 
Journal of Oncology Special Series: The Era of Genomics-Driven Cancer Medicine.  The 
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aggregation of this genomic data holds great value for oncologists, ultimately working to 
improve clinical oncology disease management (Garraway et al., 2013).  
Although such advances have the potential to narrow the gap between the 
knowledge gained from genomic data and its practical use in the clinic, Van Allen, Wagle 
and Levy (2013) acknowledge that there is an increasing disparity between the levels of 
complexity that such technologies are beginning to attain and the analytical capacity of 
oncology professionals.  Guan et al. (2012) affirm that it will require ongoing dedication 
to the application of NGS technology in oncology to enable the success of genome-driven 
cancer care. 
 
BACKGROUND 
Next generation sequencing technology in oncology: the process 
Contributors to the American Medical Association: Journal of Ethics, Erin W. 
Hofstatter, MD and Allen E. Bale, MD (2013) have described the process of sequencing 
technology in the field of oncology as “conceptually logical and simple.”  They explain 
that a patient’s tumor is first sequenced and compared to a standard control genome so 
that all of the genetic differences can be detected.  Hofstatter and Bale point out that since 
all humans have benign genetic variants that differ from any control, the patient’s 
constitutional genome is also sequenced to distinguish between germline mutations of the 
individual’s constitutional genome and somatic mutations of the tumor.  They note that 
while somatic mutations are potentially pathogenic, germline mutations are seldom 
related to cancer (but should be established nonetheless).  Mutation databases of known 
cancer genomes are then accessed to determine whether the somatic alterations identified 
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are actionable genetic variations, meaning that they are treatable with emerging 
anticancer drugs (Hofstatter & Bale, 2013).   
Case studies have illustrated some exceptional clinical outcomes for cancer 
patients as a result of tumor sequencing that altered treatment.  Chung et al. (2014) 
detected an EML4-ALK rearrangement in a 53-year-old nonsmoker with poorly 
differentiated malignant neoplasm in the lung and right upper extremity using the fully 
informative genomic panel (FoundationOne) developed by Foundation Medicine Inc.  
Based on this mutation, crizotinib was administered, and the “patient responded with 
rapid and significant volume decreases of the masses from both sites” (Chung et al., 
2014).  In another case, Palma et al. (2015) identified an FGFR3 activating mutation via 
tumor sequencing in a patient with urothelial carcinoma.  As a result, the individual 
responded exceptionally to targeted drug, pazopanib (Palma et al., 2015).  
 
Advances in genomic sequencing in oncology 
Massively parallel (“next-generation”) sequencing (MPS) has become more 
widely implemented due to significant benefits over its predecessors.  Laura MacConaill, 
PhD, (2013) of Dana-Farber Cancer Institute describes the advantages as follows:  The 
launch of MPS dramatically reduced cost of sequencing a single patient from US$70 
million by the Sanger method in 2007 to under US$5,000 in 2013.  Simultaneously, 
tremendous improvement in both sensitivity and scalability has allowed for more 
comprehensive studies with initial reports of 100-fold improved throughput over Sanger 
sequencing (2013).  Additionally, MPS is able to identify various types of aberrations in 
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the cancer genome such as “base mutations, indels, copy number alterations, and 
rearrangements” (MacConaill, 2013).   
Consequently, there has been growing use of next-generation sequencing (NGS) 
in a variety of academic and commercial settings.  For example, Memorial Sloan 
Kettering Cancer Center (MSKCC), a cancer treatment center in New York, uses next-
generation sequencing in their latest diagnostic test known as Integrated Mutation 
Profiling of Actionable Cancer Targets (MSK-IMPACT™).  MSKCC announced, 
“…MSK-IMPACT™ gives doctors an unparalleled amount of information about 
individual people’s cancers to guide their treatment” (Kiesler, 2014).  The technology has 
also spawned the creation of specialized sequencing technology companies (e.g., 
Illumina, Life Technologies) as well as companies that specialize in applying sequencing 
technology to cancer care (e.g., Foundation Medicine Inc., Caris Life Sciences) (Carlson, 
2012).   	  
Clinical utility of genomic sequencing in oncology 
 Researchers have demonstrated clinical utility of NGS for targeted tumor 
profiling in expanded studies.  Lipson et al. (2012) analyzed 24 non-small cell lung 
cancer (NSCLC) and 40 colorectal cancer (CRC) tissue specimens to detect alterations 
linked to available clinical treatments or targeted clinical trials of new therapies.  They 
identified actionable mutations in 72% of the NSCLCs and 52.2% of CRCs.  A separate 
retrospective investigation performed by Johnson et al. (2014) detected potentially 
actionable genetic mutations (defined as associated with susceptibility to an approved 
treatment or experimental therapy) in multiple cancer types (breast carcinoma, head and 
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neck cancers and melanoma).  The majority of their patients (83% of 103) had additional 
treatment options based on targeted NGS tumor sequencing.  At a median follow-up of 
4.1 months, 21% of patients received genotype-directed therapies and 61% of patients 
were in clinical trials (Johnson et al., 2014).  Since the small number of geographic 
locations limited the number of patients in trials, Johnson et al. (2014) expected that 
patient enrollment would increase as studies expand nationally.  In another study, Andre 
et al. (2012) recruited metastatic breast cancer patients to identify therapeutic targets 
based on genomic alterations.  They anticipated that up to 30% of patients would receive 
genome-directed therapy, concluding that personalized medicine is feasible for metastatic 
breast cancer. 
 There are experts in the field that view such findings differently.  Sparano, Ostrer 
and Kenny (2013) categorize the data obtained by Andre et al. (2012), as exemplifying 
the inadequacy of NGS in oncology, with fewer than 30% of screened breast cancer 
patients expected to receive targeted therapy according to initial preliminary reports 
(Sparano, Ostrer, & Kenny, 2013).  Hofstatter and Bale (2013) also cite this analysis in 
“The Promise and Pitfalls of Genomics-Driven Cancer Medicine,” questioning the cost-
benefit ratio of NGS in clinical oncology since most patients are not receiving clinically 
actionable results.  Garraway (2013) makes a similar argument in his article titled 
“Genomics-Driven Oncology: Framework for an Emerging Paradigm,” explaining that 
despite advances in sequencing technologies, the practical clinical impact of NGS “still 
pushes the limits of logistical feasibility, remains costly, and may exceed the present 
developmental therapeutic need by a large margin” (Garraway, 2013).    
In the same article, however, Garraway ultimately asserts that a significant 
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number of cancers harbor actionable variants for which targeted therapies may exist.  He 
argues that a genomics-driven approach is unlikely to benefit all cancers, but “the 
proportion with plausibly actionable genetic mutations is sufficiently high as to provide 
credence to the overarching hypothesis that tumor genetic information may ultimately 
provide widespread clinical benefit” (Garraway, 2013).  Furthermore, Johnson et al. 
(2014) argue that even “negative” sequencing results can have a clinical impact, steering 
patients toward appropriate non-targeted clinical studies (i.e., immunotherapy, 
chemotherapy) or possibly no additional treatments (Johnson et al., 2014).  They also 
claim that novel genomic findings can precipitate additional pre-clinical studies and 
future clinical trials(Johnson et al., 2014).  
Although there are conflicting opinions about the degree of utility of NGS in 
oncology today, many experts foresee its potential to revolutionize clinical practice in the 
future.  Meldrum, Doyle and Tothill (2011) suggest that discoveries made in refining our 
ability to study and understand the human genome, and in turn, the cancer genome will 
be responsible for bridging to a new era of personalized cancer medicine.  They argue 
that not only will sequencing technologies improve our understanding of the pathogenesis 
of cancer, they will impact detection, management and treatment of disease. In 
acknowledging how sequencing technologies have already greatly advanced cancer 
research efforts, MacConaill (2013) claims that they are “poised to similarly transform 
the translational oncology landscape.”   
 
Challenges of applying tumor-sequencing technology to oncology 
Most experts agree that for sequencing technologies to revolutionize oncology, 
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there are multiple obstacles that need to be addressed.  Oncology professionals identify 
the intrinsic biological nature of cancer tissue as a challenge for evaluating a specimen by 
any method because malignancies exhibit multiple degrees of histological heterogeneity 
(e.g., varying ratios of healthy cells to cancer cells, different histologic tumor grades 
within a single specimen) (Hofstatter & Bale, 2013; Kamalakaran et al., 2013). 
Kamalakaran et al. (2013) identify crucial steps that must be taken to examine and 
quantify the tissue sample, along with appropriate checkpoints to ensure integrity and 
quality of data.  
Genomic heterogeneity also interferes with the ability to accurately interpret 
genomic data.  Hofstatter and Bale (2013) describe some of the complexities involved. 
They begin by explaining that cancers, being exceedingly unstable by nature, accumulate 
a great number of genetic alterations.  As a result, detecting actionable or “driver” 
mutations proves difficult because most of the alterations are “passenger” mutations, or 
not pathogenic.  In addition, they mention the potential for variants of uncertain 
significance(Hofstatter & Bale, 2013).  Even when found in genes that are known to 
cause cancer, the impact of genetic changes is often unknown or yet to be established.  
Guan et al. (2012) also note that few detected alterations are pathogenic, and describe the 
interpretation and clinical translation of genetic variants as a bottleneck for routine use of 
NGS in clinical oncology.  Furthermore, Guan et al. (2012) explain that the driver and 
passenger mutations can change as a tumor develops, so even if a targeted therapy proves 
successful, it may suddenly stop working if the tumor develops resistance.  In the book 
Cancer Genomics: From Bench to Personalized Medicine, Dellaire, Berman and Acreci 
(2014) acknowledge this challenge and state the potential need to re-evaluate cancer care 
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moving forward, possibly coming full circle by ordering additional genomic sequencing 
of serial tumor biopsies. 
Guan et al. (2012), Kamalakaran et al. (2013) and Roychowdhury et al. (2011) 
discuss the difficulties in translating complex genomic data into clinically actionable 
cancer care at scale.  They emphasize the challenges in storing, filtering, processing and 
analyzing huge amounts of data and the need for specialized computational infrastructure.  
While describing the “superb potential” of sequencing technologies in accelerating 
precision cancer medicine, MacConaill (2013) also points out the need for a rigorous 
interpretive framework to identify and decipher complex underlying genomic 
information.  
Finally, several experts in cancer genetics have documented the ethical challenges 
that arise from the examination of comprehensive genomic data in the clinical setting, 
and the subsequent disclosure of results to oncologists and patients.  Hofstatter and Bale 
(2013) point out the potential for unanticipated incidental germline findings, indicating 
that most patients carry a “handful” of germline variants that are disease-causing in the 
homozygous state.  They explain that although such findings might not have much of an 
effect on the patient in question, they could have serious implications for family 
members.  Hofstatter and Bale (2013) also discuss circumstances when incidental 
germline findings simultaneously unveil additional diagnoses for cancer patients, such as 
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome.  Since these types of findings 
are not always entirely unanticipated, they say that pre-test counseling to review potential 
types of findings could assist in the appropriate disclosure of such results.  Hoffstater and 
Bale (2013) go on to claim that the incidental or “unsolicited” findings that prove to be 
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more problematic are the diagnoses of untreatable diseases unrelated to cancer, 
illustrating an example case involving a mutation known to cause a heritable form of 
early-onset Alzheimer dementia.  Lolkema et al. (2013) evaluate the ethical issues that 
pertain to the possible moral duty to return such germline findings.  They mention that in 
ongoing debates over whether to disclose such genetic information to patients, most agree 
that there is an ethical duty to return genetic data that is truly actionable.  Hall et al. 
(2014b), Kamalakaran et al. (2013), and Roychowdhury et al. (2011) acknowledge the 
significant need for an informed consent process that includes a way to handle germline 
incidental findings.  Meldrum et al. (2011) agrees that such ethical issues must be 
resolved, and proposes that a “more targeted approach to genome sequencing may be a 
logical next step towards widespread implementation of the technology.” 
 
Lack of knowledge of healthcare professionals working in oncology 
The latest report of the Secretary's Advisory Committee on Genetics, Health, and 
Society (SACGHS) noted significant gaps in the education and training of health 
professionals regarding the implementation of genetic testing and the competency in 
genetics and genetic testing (Ferreira-Gonzalez et al., 2008).  While tumor-sequencing 
tests have the potential to offer transformative genomic findings relevant to disease 
management, evidence suggests that medical oncologists in particular feel ill-equipped to 
implement the technology (Innocent, Ruth, & Boland, 2014).  A survey conducted of 
oncologists in varied settings to assess perceived understanding and preparedness to use 
NGS technology indicated that community oncologists were found to be “less 
knowledgeable and less experienced with it, and felt less prepared to use it clinically” 
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(Innocent et al., 2014).  Hall et al., (2014b) cite this investigation in the Journal of 
Surgical Oncology, stating that the ability of oncologists to use this rapidly emerging 
technology for their patients is affected by setting and confidence level.  Furthermore 
they mention that according to several studies, provider confidence in genomic 
proficiency influences their decision-making with regards to ordering behaviors towards 
tumor-sequencing tests (Hall, Forman, Montgomery, Rainey, & Daly, 2015).   
Presumably, low levels of confidence would disadvantage the delivery of genomics-
driven cancer medicine.  In another article titled “Conflicted Confidence: Academic 
Oncologists’ Views on Multiplex Pharmacogenomic Testing,” Hall (2014) mentions that 
the lack of experience or minimal experience beyond basic single-gene testing suggests 
the need for provider-orientated education regarding routine aspects of somatic testing, 
such as communicating potential germline implications of somatic tests.  
 
Benefits of a Team Approach 
Professionals in the field have suggested that a multidisciplinary environment in 
genomics-driven cancer care could address the oncologists’ lack of confidence.  Robert 
R. McWilliams, MD, of the Mayo Clinic demonstrated the need for a team approach 
among colleagues.  He distributed an informal survey that revealed that “70% of 
respondents ‘commonly’ did not know what to do with genomic results, and more than 
80% of respondents would find it helpful to be able to query a genomic tumor board with 
multidisciplinary expertise regarding the result” (American Society of Clinical Oncology: 
Daily News, 2015).  Kamalakaran et al. (2013) mention a collaborative approach in an 
article titled Translating next generation sequencing to practice: “For the oncology 
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experts, the decision support is usually performed by a team of bioinformaticians, 
statisticians and genetic counselors.  The importance and relevance of the mutations must 
be ascertained and presented to the oncologist in an intuitive manner.”  In describing how 
oncologists will handle the return of comprehensive genomic data, Garraway (2013) 
points out the need for additional support stating, “Considerable personnel resources 
(e.g., genetic counselors with specialized training) may be needed to ensure that patients 
understand the potential benefits and risks of receiving somatic and germline data and to 
support physicians in conveying such information.”  
 
Potential role of genetic counselors in genomics-driven oncology 
The roles of genetic counselors have expanded across multiple specialties, but 
particularly in oncology due to more widespread use of panel-based genetic testing 
resulting in variants of uncertain significance (Ormond, 2013).  Genetics experts at 
Illumina, Inc., express an increased need for genetic counselors in the implementation of 
NGS stating the following: “The complex nature and volume of the reported results 
requires professional interpretation of the testing in order to translate and synthesize the 
meaning and potential benefit to patients, and genetic counselors are uniquely suited to 
provide this service” (Swanson, Ramos, & Snyder, 2014).   
Although genetic counselors have elements of the skill-set to translate genomic 
data into purposeful information for patient care, evidence suggests that education is 
needed to improve their knowledge base of rapidly emerging sequencing technologies 
(Hall et al., 2014).  A survey regarding tumor NGS was distributed among members of 
the National Society of Genetic Counselors (NSGC) of which 693 participants responded.  
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It assessed the experience, objective knowledge (i.e., advantages/disadvantages, clinical 
barriers, clinical applicability) and perceptions of personal competence related to NGS 
genomic testing (NGSGT) in oncology.  The study revealed that genetic counselors (GC) 
are uncertain of their professional role in genomic sequencing and feel inadequately 
prepared to support NGS of tumors in the clinic setting.  Only 13% indicated that they 
had counseled for NGS tumor-sequencing tests.  While 46% of GCs in the study 
anticipated a role in tumor panel testing, almost all participants (97%) agreed that GCs 
have a role in associated germline testing.  Additionally, the survey revealed that the 
majority desire more education about NGSGT in tumors (84%) and germline (87%).  In 
concluding the study, Hall et al. (2014) suggested the following: “Lack of experience and 
knowledge deficits may adversely impact GC perceived clinical competence to help 
patients make important decision using this new technology.” 
 
Conclusion 
NGS technology is rapidly improving the field of precision oncology, but with 
this advancement comes a host of challenges, ranging from the interpretation of the 
complex cancer genome to the clinical applicability of genomic data, and of course the 
ethical delivery of genomic results.  It has been proposed that a multidisciplinary 
approach may be best suited for comprehensive cancer medicine, but studies need to 
investigate how genetic counselors, in particular could help bridge the gap between the 
genomic results of tumor profiling and the implications for the patient and family 
members.   
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Purpose of the study 
The increasing disparity between the genomic data attained by NGS technology 
and the analytical capacity of healthcare providers raises the need for a multidisciplinary 
team.  This paper aims to establish the current roles that genetic counselors, in particular, 
play in oncology and their perceived roles in the application of tumor-sequencing 
technologies.  
 
METHODS 
Participants 
Genetic counselors that work in cancer genetics in any capacity (e.g., clinical, 
laboratory and industry) were eligible to participate.   
 
Instruments 
The study consisted of a voluntary and anonymous 25-question survey distributed 
among members of NSGC.  The survey consisted of multiple choice and free-response 
questions within varied categories: demographic information, tumor-sequencing 
experience, perceived obstacles of tumor-sequencing technologies in its application and 
perceived roles of genetic counselors in the field.  The survey was generated via Survey 
Monkey, and it consisted of both mandatory and optional questions.  Participants were 
able to return to questions and change their answers.  IP addresses were not collected, and 
participants were not asked any identifying questions.  Participants did not receive any 
compensation for their participation.   
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Procedures 
The Sarah Lawrence College Institutional Review Board determined that the 
research project was exempt from ongoing IRB review (#00009775) on December 2, 
2015.  An invitation to participate in the study was distributed through the Genetic 
Counseling Student Research Survey Program to the NSGC distribution list on December 
28, 2014 (N=3245).  The objectives of the research project were stated in the email, along 
with a link for the survey and contact information for the primary investigator and 
research supervisor.  The link directed participants to complete the survey.  An additional 
reminder email was sent out on January 14, 2016. The survey was open until January 31, 
2016. 
 
Data Analysis 
 A total of 128 submissions were collected (n=128).  One hundred respondents 
were considered in the analysis of the project based on having completed at least 96.0% 
of the survey.  The data analysis was done using Survey Monkey and SPSS.  Qualitative 
questions were analyzed by classifying relevant information into common themes (open-
coding).  The primary investigator categorized the answers first; followed by an 
additional coder who was otherwise uninvolved in the project.  The inter-rater reliability 
was 92.4%. 
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RESULTS 
Demographic Information 
Participants answered questions with regards to cancer patient load, work setting and 
years of experience (Table I). 
 
Table I: Respondent demographic information 
Variable                                                                                           N = 100 
Percentage of the patients seen 
for cancer counseling 
 N % 
0% 5 5.0 
1-25% 11 11.0 
25-50% 6 6.0 
51-75% 3 3.0 
75-100% 75 75.0 
 
Type of practice  
 
Community Hospital 42 42.0 
University Hospital 41 41.0 
Private Office 7 7.0 
Laboratory 10 10.0 
 
Length of time in practice 4+ years 44 44.0 
1-3 years 39 39.0 
<1 year 17 17.0 
 
Current Practice 
Participants were asked to reflect on the use of tumor genomic sequencing in their 
institution (Table IIa), the obstacles for use of tumor profiling (Table IIb), along with 
ways in which they currently provide genetics cancer-related expertise to other medical 
professionals (Table IIc).  Two open-ended questions were included that prompted 
participants to elaborate.  One asked why participants identified a particular obstacle for 
the use of tumor profiling as the most significant, for which 52.0% (n=52) responded. 
The other open-ended question asked about the ways in which participants currently 
provide cancer-related expertise to other medical professionals.  Sixty-six (66.0%) 
	  	  
18	  
individuals elaborated, and the types of cancer-related expertise were classified into 
common themes (Table IIc).   
 
Table IIa: Current practice 
Do you work regularly with an 
oncology group(s)? 
 N = 100	  
N	  	  	  	  	  	  	  	  	  	  	  %	  
Yes 86 86.0	  
No 14 14.0	  
 
If yes, how would you rate the 
knowledge of oncology group(s)? 
 N = 91 
N          % 
Somewhat informed 59 64.8 
Very informed 20 22.0 
Slightly informed 12 13.2 
Not at all informed 0 0.0 
 
To your knowledge, are the 
oncologists at your institution using 
tumor genomic sequencing at least 
some of the time?  
  
N = 100 
N             % 
Yes 87 87.0 
No 13 13.0 
 
 
Table IIb: Current practice 
Which of the following do you perceive as primary obstacles to wider use of tumor 
genomic sequence testing? Check all that apply. 
  N = 100	  
N	  	  	  	  	  	  	  	  	  	  	  %	  
Information not yet valuable in most cases 66 66.0 
Insurance reimbursement 62 62.0 
Lack of familiarity among medical professionals 62 62.0 
Test not available 11 11.0 
Unsure 16 16.0 
 
Which of the obstacles do you think is the most significant? 
  N = 100 
N             % 
Insurance reimbursement 29 29.0 
Information not yet valuable in most cases 29 29.0 
Lack of familiarity among medical professionals 23 23.0 
Unsure 18 18.0 
Test not available 1 1.0 
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Table IIc: Current practice 
As part of your job, do 
you provide genetics 
cancer-related expertise 
to other medical 
professionals?  
  
 
 
N = 100 
N             % 
 Yes 85 85.0 
 No 15 15.0 
If you provide genetics cancer-related expertise to other medical professionals, 
please elaborate. 
 Open-ended theme N = 66	  
N	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  
Teaching (e.g., lectures, presentations, conferences) 47 71.2	  
Intra-hospital meetings (e.g., tumor boards, grand rounds) 35 53.0	  
Consult (e.g., recommendations for 
testing/management/referrals, interpretation of results) 
34 51.5	  
Support (e.g., provide support in hospital/ community 
events) 
7 10.6	  
Germline (e.g., clarify implications of germline mutations) 9 13.6	  
 
 
Potential Areas of Practice 
Participants were asked to consider the potential roles that genetic counselors would be 
equipped to play with regards to the application of tumor genomic sequencing (Table III).  
An open-ended question was included that asked participants why they identified a 
particular role as most significant, for which 56.0% (n=56) responded.  
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Table III: Future practice 
Do you feel there is a role for genetic counselors in the use of tumor genomic 
sequence testing? 
  N = 100 
N             % 
Yes 80 80.0 
Unsure 20 20.0 
No 0 0.0 
 
If yes, which of the following roles do you believe genetic counselors can play in 
regard to tumor genomic sequencing? Check all that apply. 
  N = 100 
N             % 
Identify and discuss incidental germline information 
uncovered by testing 
91 97.9 
Serve as a resource for physicians who may not be 
comfortable with genomic testing 
71 76.3 
Educate medical students, residents and fellows about 
tumor genomic sequencing 
65 69.9 
Educate physicians and medical professionals on issues 
around informed consent 
63 67.7 
Post-test counseling of patients to help interpret tumor 
sequence testing results 
61 65.6 
Pre-test counseling of patients to help explain tumor 
sequence testing/ informed consent 
41 44.1 
 
If you answered the previous question, which role do you think is the most 
significant? 
 N = 90 
N             % 
 Identify and discuss incidental germline information 
uncovered by testing 
51 56.7 
 Post-test counseling of patients to help interpret tumor 
sequence testing results 
11 12.2 
 Educate physicians and medical professionals on issues 
around informed consent 
9 10.0 
 Pre-test counseling of patients to help explain tumor 
sequence testing/ informed consent 
8 8.9 
 Serve as a resource for physicians who may not be 
comfortable with genomic testing 
7 7.8 
 Educate medical students, residents and fellows about 
tumor genomic sequencing 
2 2.2 
 Unsure 2 2.2 
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Interest in Further Education 
Additional questions asked participants to rate their levels of interest in further education 
with respect to tumor profiling and potential topics to be covered in a tumor genomic 
sequencing course (Table IV).  Of the 97.0% of participants that were interested, 43 
agreed that they would be interested in participating in a course on tumor genomics, 54 
indicated that they strongly agreed and 3 were neutral. 
 
Table IV: Further Education 
I would be interested in participating in a course on tumor genomics aimed at 
genetic counselors. 
 N = 100 
N             % 
 Strongly Agree 54 54.0 
Agree 43 43.0 
Neutral 3 3.0 
 
Below are potential topics to be covered in a tumor genomics course for genetic 
counselors. Please rate your interest in each of the following topics. 
 N = 97 
Weighted      
Total      Average 
 Information about tumor genotyping (e.g., driver vs. 
passenger mutations) 
97 4.22 
 How to identify patients who are good candidates for 
sequencing 
96 4.32 
 The relationship between tumor sequencing results and 
germline information 
95 4.86 
 How results of tumor sequencing can influence treatment 
decisions 
97 4.37 
 Current companies offering tumor sequencing and tumor 
sequencing information services (e.g., Foundation 
Medicine, N-of-One, etc.) 
97 3.92 
 Advantages and disadvantages of various sequencing 
technologies 
97 4.29 
 Available resources for interpretation of tumor genomic 
sequencing 
97 4.72 
 
 
	  	  
22	  
DISCUSSION 
 
Current Practice 
Most participants reported that they provide genetics cancer-related expertise to 
other medical professionals (85.0%, n=85).  Of the 66 individuals who elaborated, open-
ended responses most frequently involved teaching other healthcare providers through 
lectures, presentations and conferences (71.2%, n=47), followed by collaborating in intra-
hospital meetings such as tumor boards and grand rounds (53.0%, n=35).  A significant 
number of counselors described consulting with other healthcare providers, which 
included recommendations for referrals, surveillance, management and genetic testing 
(51.5%, n=34).  Other common responses involved providing support internally and/or 
throughout the community (10.6%, n=7) and clarifying the implications of germline 
findings (13.6%, n=9).   
The majority of respondents indicated that they had more than one role in 
educating other medical professionals (69.7% n=46).  One responder described multiple 
categories in providing expertise to other hospital providers: “I have given a talk for GI 
fellows at my hospital, and started to teach a nursing class this year.  I also attend solid 
tumor conference at my hospital to provide input on cases that may need germline genetic 
testing, and consult less formally about genetic testing for patients with medical 
professional from various departments.”   
Other participants specifically reported educating physicians with oncology 
training.  One genetic counselor said, “I have given genetics presentations to various 
oncology specialists about the updates in cancer genetics in-services and tumor board 
education to medical oncologists, surgeons and radiation oncologists.”  Another 
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described assisting oncology clinicians with the interpretation of tumor genomic 
sequencing results: “I work closely with the pediatric hematologist-oncologists at my 
institution. I explain results of previously tested patients, as well as clarifying cases I 
have consulted on.  I also help them understand tumor-sequencing results (such as 
Foundation Medicine) testing.” 
Among the large number of responders, 86 (86.0%) that reported working 
regularly with an oncology group or several oncology groups, only 22.0% (n=20) rated 
the knowledge of cancer genetics by their oncology groups as very informed.  Still 87 
(87.0%) reported that oncologists at their institution were using tumor genomic 
sequencing at least some of the time.  
A majority of the responders (62.0%, n=62) identified a lack of familiarity among 
medical professionals with regards to tumor genomic sequencing as a significant obstacle 
to its wider application, along with insurance reimbursement (62.0%, n=62) and 
information not yet valuable in most cases (66.0%, n=66).  A smaller number (11.0%, 
n=11) identified testing not yet available as an obstacle to more widespread use.  When 
responders were prompted to choose the most significant obstacle, the same three choices 
were selected with the most frequency at 23.0%, 29.0% and 29.0% respectively, and one 
responder (1.0%) chose ‘test not yet available’ (Table III). 
Among the 29 participants who chose insurance reimbursement as the primary 
barrier, both expense to patients and insurance company policies were identified as 
issues.  Approximately a third of the 29 (34.5%, n=10) expressed that medical 
professionals are weary of the cost, mentioning that the out of pocket expense is too high, 
especially for middle and low-income populations.  A few other participants said that 
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insurance companies have not instituted policies in this area of genetic testing, as they 
still view tumor profiling as exploratory, and thus will not fund it.  One responder wrote, 
“Internal 3rd party insurance payers have internal policies that deem this ‘experimental;' 
there is no peer reviewed literature proving the utility of the testing.” 
Limited clinical utility was also mentioned by 17 of the 29 participants that 
indicated that the primary obstacle to the widespread use of tumor genomic sequencing is 
that ‘information is not yet valuable in most cases.’  Respondents often noted in 
comments that the testing rarely benefits the patient in terms of adjusting medical 
management.  As one participant reported: “Thus far, in the results that I have seen, it is 
uncommon for the result of tumor sequencing to alter the patient's treatment options.”  
Another respondent stated, “Most genomic alterations identified on tumor NGS do not 
yet have a matched FDA-approved drug or clinical trial.”  Four participants argued that 
‘information not yet valuable’ is the biggest limitation due to a lack of guidelines in terms 
of how to handle tumor genomic sequencing results.  One genetic counselor said, “It ties 
into lack of ability to and/or understanding of how to interpret and apply results to help 
determine appropriate treatment course.”  Another respondent said, “I think that the lack 
of information and the subsequent lack of NCCN Guidelines for these test results are 
stopping our docs (who rely heavily on NCCN) from ordering this kind of testing.”  
Concerns about to a gap in knowledge were similarly expressed by the 23 (23.0%) 
respondents who chose a lack of familiarity among health care providers as the primary 
barrier to tumor profiling.  Eight (34.8%) of these respondents indicated that oncologists 
are less likely to order tumor genomic sequencing because they are often uninformed 
about how and when to request testing and how to best use the resulting information.  
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Two individuals reported that the current developments in technology are very difficult 
for busy oncologists to keep up with.  One respondent who chose lack of familiarity as a 
barrier was more specific: “Data regarding clinical applicability of results; too many labs 
with varying yet similar tests and MDs do not know when to order which.” 
 
Potential Areas of Practice 
With respect to anticipated roles in the clinical application of tumor genomic 
sequencing, most responders (80.0%, n=80) felt that genetic counselors should play a 
part.  In fact, the majority of responders identified 5 roles that genetic counselors would 
be equipped to play in tumor genomic analysis.  The largest number, 91 (97.9%) 
indicated identifying and discussing incidental germline findings uncovered by testing, 
followed by serving as a resource for physicians who may not be comfortable with 
genomic testing 76.3% (n=71), educating medical students, residents and fellows about 
tumor genomic sequencing 69.9% (n=65), educating medical professionals on issues 
around informed consent 67.7% (n=63), and post-test counseling of patients to help 
interpret tumor sequencing results 65.6% (n=61).  The duty of pre-test counseling for 
patients to help explain tumor sequence testing and informed consent was identified as a 
potential role by a smaller number of responders 44.1% (n=41).    
When asked which role was most significant, the most common response was 
‘review of germline results’ (56.7%, n=51).  Other responses were fairly evenly split 
between ‘post-test counseling’ (12.2%, n=11), ‘educate physicians and professionals 
around informed consent’ (10.0%, n=9), ‘pre-test counseling’ (8.9%, n=8), and ‘resource 
for physicians’ (7.8%, n=7), however, comments suggested considerable overlap in the 
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concerns and expectations among respondents regardless of their answer.  The issue of 
germline mutations was reflected in the open-ended response from a participant who 
indicated that the primary role was pre-test counseling: “I chose this as the most 
significant since it educates the patient in the very beginning that way there is no surprise 
of a germline incidental result afterwards.”  Among the 11 responders who chose post-
test counseling of patients one stated, “Post-test counseling will allow GCs to explain the 
results fully and appropriately to the patients, while simultaneously allowing for the 
identification and proper subsequent germ line testing.”  One of the 10 participants who 
indicated that the primary role was educating physicians who may not be comfortable 
with informed consent said, “Many patients have no idea about the difference between 
somatic and germline testing.  Additionally they are not informed that the testing could 
yield information that could be relevant for family members.”  
Respondents also commonly expressed their confidence with regards to the 
application of genomic testing, in contrast with oncologists’ lack of experience or 
minimal experience beyond basic single-gene testing (Hall 2014).  One respondent, 
speaking of post-test counseling to help interpret tumor sequence results, said: “This 
seems to be the area where there is the most confusion and where a GC could have the 
most significant role.”  Participants indicated that these roles were consistent with the 
skill set and training of genetic counselors. One respondent wrote, “I think that 
explaining incidental germ line information is an area where GCs bring expertise above 
and beyond that of the patient's oncologist.”  Others stated, “It is the most relevant to the 
genetic counseling profession and least well-addressed by other medical professionals.” 
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and “Physicians only briefly consent to germline findings when ordering tumor tests, but 
these can have a larger implication of global health of the patient and family members.” 
Another theme among open-ended responses was the shortage of genetic 
counselors (6.0%, n=6).  A respondent speaking of pre-test counseling said, “I think this 
role would be the most difficult to implement as there are not enough genetic counselors 
to likely cover this new demand.”  A respondent among those who favored distinguishing 
incidental germline findings wrote, “I end up explaining what the test even was most of 
the time, which definitely speaks to the need for pre-test counseling but it's not something  
GCs have time for.”  Due to the shortage, a genetic counselor suggested the importance 
of educating medical professionals about informed consent stating, “If paired 
tumor/germline testing begins, this would be extremely important and there are not 
enough GCs to do the pre-test counseling and consent so education and handouts would 
be necessary.”  Another participant added: “There won't be enough GCs to provide pre 
and post test-counseling for all patients having tumor profiling, but being a resource for 
the questions that come up will really help.” 
 
 
Study limitations  
Since the research survey was distributed through the distribution list of the 
National Society of Genetic Counselors (NSGC), only NSGC members were able to 
participate.  For this reason, the study did not account for experiences and opinions of 
non-NSGC members.  As with any research study, the individuals who were most likely 
to participate are those who had interest or strong feelings on the topic being investigated. 
This is a concern considering the low response rate of 3.1% among NSGC members (N = 
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3245), although eligibility criteria may have limited response, as only those who 
specialize in oncology could participate. 
 
Conclusion 
Based on this study, genetic counselors today already play a significant role as 
part of multidisciplinary care in oncology.  With regards to tumor genomic sequencing, 
survey results indicate that there is variability in the opinions of what the obstacles are to 
widespread use.  Nevertheless, the data suggests that genetic counselors foresee multiple 
roles that they are adept to handle in the context of tumor genomic analysis, with 
information involving germline findings consistently specified as the most important and 
relevant to the profession.  Given the shortage of genetic counselors, some respondents 
suggest that a comprehensive role as a resource in educating other medical professionals 
might inevitably be the most feasible way to ensure the appropriate delivery of germline 
information.  
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